Loading...
•
Jun 30, 2023
Aclaris Therapeutics Q2 2023 Earnings Report
Aclaris Therapeutics reported financial results for the second quarter of 2023 and provided a corporate update.
Key Takeaways
Aclaris Therapeutics reported a net loss of $29.6 million on total revenue of $1.9 million for the second quarter of 2023. The company's cash, cash equivalents, and marketable securities totaled $210.8 million as of June 30, 2023, which is expected to fund operations through the end of 2025.
Completed enrollment in Phase 2b trial of zunsemetinib in rheumatoid arthritis, with data expected in Q4 2023.
Phase 2a trial of zunsemetinib in psoriatic arthritis is ongoing, with topline data expected in the first half of 2024.
Phase 2b trial of ATI-1777 in atopic dermatitis is ongoing, with topline data expected in the second half of 2023.
Aclaris expects to report data for ATI-2138 in September 2023 and initiate clinical development activities for ATI-2231 in the second half of 2023.
Aclaris Therapeutics
Aclaris Therapeutics
Aclaris Therapeutics Revenue by Segment
Revenue by Segment
Contract research Revenue
CapyFin.comLicensing Revenue
CapyFin.com Forward Guidance
Aclaris anticipates that its cash, cash equivalents and marketable securities as of June 30, 2023 will be sufficient to fund its operations through the end of 2025.
Revenue & Expenses
Visualization of income flow from segment revenue to net income